文献速递胃肠动力与功能性疾病

NGM282(一种FGF19变体)对功能性便秘患者结肠传输与肠道功能的影响:一项随机2期试验

Effects of NGM282, an FGF19 variant, on colonic transit and bowel function in functional constipation: a randomized phase 2 trial.
PubMed 文献 · Am J Gastroenterol · 2018-05-02

这项随机、平行组、安慰剂对照的14天2期试验在符合罗马III标准且基线24小时结肠传输几何中心<3.0的功能性便秘患者中,评估每日皮下注射1 mg或6 mg NGM282对结肠传输、排便频率与性状、肝脏胆汁酸合成、粪便脂肪及胆汁酸的影响。结果显示NGM282改变肠道功能并显著加速胃与结肠传输,剂量相关效应见于24小时几何中心;最常见不良事件为食欲增加、注射部位反应和腹泻。

要点

  • NGM282显著加速功能性便秘患者的胃排空与结肠传输,并改变排便频率、性状与排出难易度。
  • 24小时结肠传输几何中心呈剂量相关效应,但胃排空与48小时几何中心未见剂量相关效应。
  • KLB SNP存在治疗交互作用,携带次要A等位基因者结肠传输增加更明显(p=0.056)。

核心结论

  • NGM282显著影响胃排空与结肠传输,与观察到的临床症状一致;其促动力作用的具体机制需进一步研究。

研究设计与样本

  • 随机、平行组、安慰剂对照、14天2期试验,纳入符合罗马III标准且基线24小时结肠传输几何中心<3.0的功能性便秘患者,比较每日皮下注射NGM282 1 mg、6 mg与安慰剂。
  • 探索了KLB、FGFR4与TGR5(GPBAR1)基因SNP与治疗之间的交互作用。
  • 统计分析采用总体ANCOVA(α=0.025,以基线为协变量),三组间进行三对两两比较(α=0.008)。

主要发现

  • 总体而言,NGM282改变肠道功能(排便次数、更稀的粪便性状及排便难易度改善)并显著加速胃与结肠传输。
  • 24小时几何中心呈剂量相关效应,但胃排空与48小时几何中心未见剂量相关效应。
  • 粪便脂肪或粪便重量无差异,但NGM282组粪便总胆汁酸排泄减少。
  • 最常见不良事件为食欲增加(安慰剂0例、1 mg组2例、6 mg组9例)、注射部位反应(安慰剂2例、1 mg组4例、6 mg组8例)和腹泻(1 mg组1例、6 mg组4例)。
  • KLB SNP存在治疗交互作用,携带次要A等位基因者结肠传输增加更明显(p=0.056)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出NGM282促动力作用的具体机制需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: NGM282 is an analog of fibroblast growth factor 19 (FGF19), a potent inhibitor of bile acid (BA) synthesis in animals and humans. In phase 2 trials in type 2 diabetes and primary biliary cholangitis, NGM282 was associated with dose-related abdominal cramping and diarrhea. We aimed to examine effects of NGM282 on colonic transit, stool frequency and consistency, hepatic BA synthesis (fasting serum C4), fecal fat, and BA in functional constipation (FC). METHODS: Two-dose NGM282 (1 and 6 mg, subcutaneously daily), parallel-group, randomized, placebo-controlled, 14-day study in patients with FC (Rome III criteria) and baseline colonic transit 24 h geometric center (GC) <3.0. We explored treatment interaction with SNPs in genes KLB, FGFR4, and TGR5 (GPBAR1). STATISTICAL ANALYSIS: overall ANCOVA at α = 0.025 (baseline as covariate where available), with three pairwise comparisons among the three groups (α = 0.008). RESULTS: Overall, NGM282 altered bowel function (number of bowel movements, looser stool form, and increased ease of passage) and significantly accelerated gastric and colonic transit. Dose-related effects were seen with GC 24 h, but not with gastric emptying (GE) and GC 48 h. There were no differences in fecal fat or weight, but there was reduced fecal total BA excretion with NGM282. The most common adverse events were increased appetite (n = 0 with placebo, 2 with 1 mg, 9 with 6 mg), injection site reaction (n = 2 placebo, 4 with 1 mg, 8 with 6 mg), and diarrhea (n = 1 with 1 mg and 4 with 6 mg NGM282). There was treatment interaction with KLB SNP, with greater increase in colonic transit in participants with the minor A allele (p = 0.056). CONCLUSION: NGM282 significantly impacts GE and colonic transit, consistent with the observed clinical symptoms. The specific mechanism of prokinetic activity requires further research.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Oduyebo I, Camilleri M, Nelson AD, et al. Effects of NGM282, an FGF19 variant, on colonic transit and bowel function in functional constipation: a randomized phase 2 trial. Am J Gastroenterol. 2018. PMID: 29717197. doi:10.1038/s41395-018-0042-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。